Modality
mAb
MOA
FGFRi
Target
SOS1
Pathway
Checkpoint
BCCCRC
Development Pipeline
Preclinical
~Jan 2015
→ ~Apr 2016
Phase 1
~Jul 2016
→ ~Oct 2017
Phase 2
~Jan 2018
→ ~Apr 2019
Phase 3
Jul 2019
→ Oct 2029
Phase 3Current
NCT05505057
1,522 pts·BCC
2022-11→2026-09·Terminated
NCT05054122
1,965 pts·CRC
2022-04→2025-01·Not yet recruiting
NCT04377739
1,965 pts·BCC
2022-10→2029-10·Completed
+1 more trial
8,194 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-01-181.2y agoPh3 Readout· CRC
2026-09-256mo awayPh3 Readout· BCC
2029-04-243.1y awayPh3 Readout· BCC
2029-10-193.6y awayPh3 Readout· BCC
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P3
Complet…
P3
Not yet…
P3
Complet…
P3
Termina…
Catalysts
Ph3 Readout
2025-01-18 · 1.2y ago
CRC
Ph3 Readout
2026-09-25 · 6mo away
BCC
Ph3 Readout
2029-04-24 · 3.1y away
BCC
Ph3 Readout
2029-10-19 · 3.6y away
BCC
CompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05505057 | Phase 3 | BCC | Terminated | 1522 | ORR |
| NCT05054122 | Phase 3 | CRC | Not yet recr... | 1965 | HAM-D |
| NCT04377739 | Phase 3 | BCC | Completed | 1965 | VA |
| NCT07548939 | Phase 3 | BCC | Completed | 2742 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| Fixaosocimab | TG Therapeutics | Phase 2/3 | SOS1 | |
| Zanurapivir | Immunocore | Phase 1 | SOS1 | |
| VYG-2970 | Voyager | Phase 3 | JAK1 |